Hyper-IgM Syndrome
A rare group of primary immunodeficiencies in which the immune system cannot properly switch antibody production from IgM to IgG, IgA, and IgE, leading to recurrent infections.
- Rare primary immunodeficiency
- Recurrent bacterial infections
- Immunoglobulin replacement therapy
- Curative transplant option in select cases
- Estimated Prevalence
- 1 in 1,000,000
- Main Genetic Cause
- CD40LG, AICDA, or UNG Mutation
- Typical Onset
- Infancy–Early Childhood
- Advanced Therapies
- Stem Cell Transplant (Type 1)
What Is Hyper-IgM Syndrome?
Hyper-IgM Syndrome is a group of rare primary immunodeficiencies in which B lymphocytes are unable to properly switch from producing IgM antibodies to IgG, IgA, and IgE. This results in normal or elevated IgM levels but low levels of the other antibody classes, leaving patients vulnerable to recurrent bacterial, and in some forms opportunistic, infections. The X-linked form (Type 1), caused by CD40LG mutations, is the most severe and well-characterized.
Types of Hyper-IgM Syndrome
Several genetic defects can cause Hyper-IgM Syndrome, each affecting a different step in antibody class switching.
Symptoms of Hyper-IgM Syndrome
Symptoms typically begin in infancy with recurrent infections that may be more frequent or severe than expected for age.
Causes and Risk Factors
Hyper-IgM Syndrome results from inherited mutations in genes required for B-cell antibody class switching, with the X-linked form being the most prevalent.
How Hyper-IgM Syndrome Is Diagnosed
Diagnosis relies on immunoglobulin testing, functional immune studies, and genetic confirmation.
Disease Severity Classification
Hyper-IgM Syndrome is not staged like cancer, but severity is generally assessed by infection burden, organ involvement, and presence of opportunistic infections.
Standard Treatment Approach
Treatment centers on replacing missing antibodies, preventing opportunistic infections, and, for severe X-linked disease, considering curative transplant.
Advanced and Emerging Therapies
For severe X-linked Hyper-IgM Syndrome, stem cell transplant offers the potential for a cure, while ongoing research explores gene-based approaches.
Hematopoietic Stem Cell Transplant
Allogeneic HSCT for Type 1 Disease
Can restore normal immune function and resolve the underlying defect in eligible patients with a suitable donor.
Immunoglobulin Replacement
IVIG / Subcutaneous Immunoglobulin
Mainstay supportive therapy to maintain protective antibody levels.
Gene Therapy Research
Investigational Gene Correction for CD40LG
Early-stage research exploring gene therapy as an alternative to transplant.
Liver Disease Management
Specialized Hepatology Care
For patients developing sclerosing cholangitis, coordinated hepatology management, including consideration of liver transplant in advanced cases.
Key Biomarkers and Laboratory Markers
Immunoglobulin profiling and functional assays are central to diagnosis and ongoing monitoring.
When to Seek a Second Opinion
Specialist input can clarify diagnosis, guide treatment intensity, and inform decisions around curative therapy.
Clinical Trials and Research
Outlook and Long-Term Prognosis
With appropriate immunoglobulin replacement and infection prevention, many patients, particularly those with non-X-linked forms, do well long-term; X-linked disease carries a more variable course influenced by liver and opportunistic infection risk.
Supportive and Quality-of-Life Care
Comprehensive supportive care addresses nutrition, infection prevention, and the emotional impact of a chronic immune disorder.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize immunology records and connect with specialists experienced in managing Hyper-IgM Syndrome, including transplant evaluation.
Get a free case reviewFrequently Asked Questions About Hyper-IgM Syndrome
Hyper-IgM Syndrome is a rare group of primary immunodeficiencies in which the immune system cannot properly switch antibody production from IgM to other antibody types, leading to recurrent infections.
It is caused by inherited mutations in genes required for antibody class switching, most commonly CD40LG in the X-linked form, or AICDA and UNG in autosomal recessive forms.
X-linked (Type 1) disease also disrupts T-cell signaling, increasing the risk of opportunistic infections and liver complications beyond the antibody deficiency seen in other forms.
Diagnosis relies on finding low IgG and IgA with normal or elevated IgM, supported by functional testing of CD40 ligand expression and confirmed with genetic testing.
Hematopoietic stem cell transplant can be curative for eligible patients, particularly those with severe X-linked disease; other forms are typically managed long-term with immunoglobulin replacement.
Recurrent bacterial sinus, ear, and lung infections are common to all forms, while X-linked disease carries additional risk of opportunistic infections such as Pneumocystis jirovecii pneumonia.
Yes. The X-linked form predominantly affects males and is inherited from carrier mothers, while AICDA and UNG deficiency follow autosomal recessive inheritance affecting both sexes.
It involves regular infusions of antibodies (IVIG or subcutaneous immunoglobulin) to provide the protective antibody levels the body cannot produce on its own.
Yes, particularly in X-linked disease, where sclerosing cholangitis and other biliary tract complications can develop and require ongoing monitoring.
Yes. CancerFax can help you organize and send your medical reports for specialist review, coordinate a second opinion, and explore access to advanced therapies such as stem cell transplant, including international coordination where relevant.
Need Help Navigating Hyper-IgM Syndrome Care?
Send your medical reports for review and let our team help you connect with specialists and explore advanced treatment options.